약학회지 (YAKHAK HOEJI)

  • 제55권2호
  • /
  • Pages.116-120
  • /
  • 2011
  • /
  • 0377-9556(pISSN)
  • /
  • 2383-9457(eISSN)
대한약학회 (The Pharmaceutical Society of Korea)
권호 표지

동맥혈관 평활근세포 증식에 대한 오보바톨 유도체(A-8)의 억제효과

Inhibitory Effects of A-8 on Abnormal Rat Aortic Vascular Smooth Muscle Cell Proliferation

  • Lim, Yong (Department of Clinical Laboratory Science, Dong-eui University) ;
  • Lee, Mi-Yea (Department of Social Welfare, World Cyber College) ;
  • Tudev, Munkhtsetseg (College of Pharmacy and CBITRC, Chungbuk National University) ;
  • Park, Eun-Seok (College of Pharmacy and CBITRC, Chungbuk National University) ;
  • Jung, Jae-Kyung (College of Pharmacy and CBITRC, Chungbuk National University) ;
  • Yun, Yeo-Pyo (College of Pharmacy and CBITRC, Chungbuk National University)
  • 투고 : 2010.12.24
  • 심사 : 2011.04.11
  • 발행 : 2011.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Abnormal proliferation of vascular smooth muscle cells (VSMCs) plays an important role in the development and progression of proliferative cardiovascular diseases, including hypertension and atherosclerosis. To find antiproliferative agent (A)-8 had inhibitory effect on VSMCs proliferation. Therefore, we examined the antiproliferative effect of A-8, a newly synthesized obovatol derivative. To investigate the antiproliferative effect of A-8, we examined cell counting and [$^3H$]-thymidine incorporation assays. The pre-incubation of A-8 (1~4 ${\mu}M$) significantly inhibited proliferation and DNA synthesis of 5% fetal bovine serum (FBS)-stimulated rat aortic VSMCs in concentration-dependent manner. Whereas, A-8 did not show any cytotoxicity in rat aortic VSMCs in this experimental condition by WST-1 assay. In addition, A-8 significantly inhibited 5% FBS-induced cell cycle progression in rat aortic VSMCs. These results show that A-8 may be developed as a potential antiproliferative agent for treatment of angioplasty restenosis and atherosclerosis. Furthermore, A-8 should be examined for further clinical application either as a single agent or in combination with other angioplasty restenosis or atherosclerosis agents.

키워드

참고문헌

  1. Abelson, P. H. : Flaws in risk assessments. Science 270, 215 (1995). https://doi.org/10.1126/science.270.5234.215
  2. Lusis, A. J. : Atherosclerosis. Nature 407, 233 (2000). https://doi.org/10.1038/35025203
  3. Garas, S. M., Huber, P. and Scott, N. A. : Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol. Ther. 92, 165 (2001). https://doi.org/10.1016/S0163-7258(01)00168-1
  4. Kearney, M., Ann, P., Laura, H., Douglas, W., Vicente, A., Robert, S., Kenneth, R. and Jeffrey, M. I. : Histopathology of instent restenosis in patients with peripheral artery disease. Circulation 95, 1998 (1997). https://doi.org/10.1161/01.CIR.95.8.1998
  5. Schwartz, S. M. : Smooth muscle migration in atherosclerosis and restenosis. J. Clin. Invest. 99, 2814 (1997). https://doi.org/10.1172/JCI119472
  6. Doevendans, P. A. and Eys, G. : Smooth muscle cells on the move: the battle for actin. Cardiovasc. Res. 54, 499 (2002). https://doi.org/10.1016/S0008-6363(02)00395-4
  7. Lee, M. S., Yang, J. E., Choi, E. H., In, J. K., Lee, S. Y., Lee, H., Hong, J. T., Lee, H. W., Suh, Y. G. and Jung, J. K. : Synthesis of obovatol derivatives and their preliminary evaluation as antitumor agents. Bull. Korean Chem. Soc. 28, 1601 (2007). https://doi.org/10.5012/bkcs.2007.28.9.1601
  8. Ross, R. : The pathogenesis: a perspective for the 1990s. Nature 362, 801 (1993). https://doi.org/10.1038/362801a0
  9. Braun-Dullaeus, R. C., Mann, M. J., Sedding, D. G., Sherwood, S. W., von der Leyen, H. E. and Dzau, V. J. : Cell cycledependent regulation of smooth muscle cell activation. Arterioscler. Thromb. Vasc. Biol. 24, 845 (2004). https://doi.org/10.1161/01.ATV.0000125704.28058.a2